Academic Journal
Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.
| Τίτλος: | Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study. |
|---|---|
| Συγγραφείς: | Seguchi K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Hashimoto T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Fujisawa T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shibuki T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Morizane C; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Nonomura N; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan., Iwata H; Department of Advanced Clinical Research and Development, Nagoya City University, Nagoya, Japan., Watari H; Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan., Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Namikawa K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Naito Y; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Bando H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tyoshino@east.ncc.go.jp.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. tyoshino@east.ncc.go.jp. |
| Πηγή: | International journal of clinical oncology [Int J Clin Oncol] 2026 Aug; Vol. 31 (8), pp. 1431-1440. Date of Electronic Publication: 2026 Jun 06. |
| Τύπος έκδοσης: | Journal Article; Observational Study; Multicenter Study; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1998- : Tokyo : Springer-Verlag Tokyo Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996- |
| Ιατρικοί όροι (MeSH): | Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/genetics , Oncologists*/standards , Certification*, Japan/epidemiology ; Humans ; Female ; Male ; Retrospective Studies ; Aged ; Middle Aged ; Neoplasm Metastasis |
| Περίληψη: | Background: Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with treatment quality and survival. Methods: This retrospective cohort study used data from the SCRUM-Japan MONSTAR-SCREEN observational study, a nationwide multicenter genomic screening program enrolling patients from 2019 to 2022. Standard treatment implementation rates were compared across cancer types as a secondary outcome. The primary outcome was overall survival (OS) in patients with metastatic colorectal cancer (mCRC) using Kaplan-Meier analysis and Cox proportional hazards regression with sequential adjustment for clinical and molecular covariates. Results: Among 2,184 patients, standard treatment rates were comparable between board-certified and non-board-certified groups (97.0% vs. 96.9%). In 358 patients with mCRC, enrollment by a board-certified physician was associated with longer OS (median, 36.5 vs. 30.7 months; hazard ratio (HR): 0.66, 95% CI 0.50-0.87; log-rank p = 0.003) even after adjustment for age, sex, tumor sidedness, region, trial participation, molecular targeted therapy, metastatic organ count (HR, 0.73; 95% CI 0.55-0.97; p = 0.029), and after additional adjustment for RAS and BRAF V600E status (HR, 0.64; 95% CI 0.47-0.88; p = 0.005). Board-certified physicians used molecular targeted therapy more frequently (89.5% vs. 80.4%; p = 0.036). Conclusions: JSMO board certification was independently associated with improved OS in mCRC despite comparable guideline adherence, suggesting that specialist expertise extends beyond treatment selection. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Conflict of interest: T. Hashimoto reports speakers’ bureau from CytoGen, Myriad Genetics, Inc., Miyarisan Pharmaceutical, Inc., Guardant Health Pte Ltd., Takeda Pharmaceutical, and Takata Pharmaceutical; research funding from Takeda Pharmaceutical and TEMPUS, Inc.; and advisory role with Guardant Health Pte Ltd. T. Fujisawa reports honoraria from Amelieff, AstraZeneca, and MSD. T. Shibuki reports personal fees from AstraZeneca and Novartis Pharma. S. Okano reports personal fees from Taiho Pharmaceutical, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, and Nihon Servier. C. Morizane reports grants from Eisai, Yakult, Ono, Taiho, J-Pharma, AstraZeneca, Merck, Daiichi Sankyo, and Boehringer Ingelheim; consulting fees from Yakult, MSD, Nihon Servier, Boehringer Ingelheim, and Taiho; and honoraria from Novartis, Yakult, Teijin Pharma, Taiho, Eisai, MSD, and AstraZeneca. N. Nonomura reports lecturer fees from Janssen, Pfizer, Astellas, Takeda, Ono, Novartis, MSD, AstraZeneca, Merck, Bayer, Bristol-Myers Squibb (BMS); and research expenses from J-Oil Mills, Taiho, Nippon Shinyaku, Pfizer, Astellas, and AstraZeneca. H. Iwata reports grant from Chugai, Daiichi Sankyo, and AstraZeneca; consulting fees from Chugai, Daiichi Sankyo, AstraZeneca, MSD, Eli Lilly, Pfizer, and Gilead; and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. H. Watari reports honoraria from AstraZeneca, Takeda, MSD, and Chugai. K. Namikawa reports honoraria from Ono, Novartis, BMS, MSD, LEO Pharma, and Kaken Pharmaceutical; served as an advisory board for Novartis, MSD, Rakuten Medical, Taiho, and Chugai; and received institutional research grants from HUYABIO International, Takara Bio, MSD, and Toray Industries. Y. Naito reports research funding (to institution) from AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai Pharmaceutical, Bayer, Takeda Pharmaceutical, Anthos Therapeutics, and Gilead Sciences; consulting fees from AstraZeneca, Eisai, Gilead Sciences, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Bayer, Daiichi Sankyo, and Ono Pharmaceutical; and speakers’ bureau from AstraZeneca, Eisai, Ono Pharmaceutical, Guardant Health, Takeda Pharmaceutical, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, PDR Pharma, Nihon Kayaku, Taiho Pharmaceutical, Bristol Myers Squibb, Bayer, Daiichi Sankyo, MSD, and Gilead Sciences. H.Bando reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Guardant Health. T. Yoshino reports honoraria from Chugai, Takeda, Merck, and Ono; consulting fees from Sumitomo Corp, and Indivumed; and research grants from Bristol-Myers, Chugai, Caris, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., MSD, Miyarisan, Natera, Nippon Boehringer Ingelheim, Ono, Pfizer, Sysmex, Taiho, and Takeda. The other authors declare no potential conflicts of interest. |
| References: | JAMA. 2023 Apr 18;329(15):1271-1282. (PMID: 37071094) Esophagus. 2024 Oct;21(4):411-418. (PMID: 39158676) J Clin Oncol. 2000 Jun;18(11):2327-40. (PMID: 10829054) Breast Cancer. 2021 May;28(3):698-709. (PMID: 33398775) J Gynecol Oncol. 2018 Mar;29(2):e23. (PMID: 29400016) JCO Glob Oncol. 2024 Oct;10:e2400333. (PMID: 39509661) Cancer Sci. 2021 Nov;112(11):4425-4432. (PMID: 34510657) Oncologist. 2021 Sep;26(9):e1609-e1618. (PMID: 33973301) Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: 28693043) J Surg Oncol. 2012 Sep 1;106(3):219-23. (PMID: 22105839) Nat Med. 2020 Dec;26(12):1859-1864. (PMID: 33020649) Clin Lung Cancer. 2017 Nov;18(6):706-718. (PMID: 28601387) Surg Endosc. 2021 Oct;35(10):5480-5488. (PMID: 32989545) Ann Oncol. 2018 Jan 1;29(1):44-70. (PMID: 29155929) Adv Radiat Oncol. 2022 Mar 08;7(5):100938. (PMID: 35469182) Gan To Kagaku Ryoho. 2024 Jan;51(1):45-52. (PMID: 38247091) J Natl Cancer Inst. 2006 Feb 1;98(3):172-80. (PMID: 16449677) JCO Glob Oncol. 2022 Mar;8:e2100314. (PMID: 35245099) Gynecol Oncol. 2020 Jun;157(3):716-722. (PMID: 32217002) |
| Contributed Indexing: | Keywords: Board certification; Chemotherapy; Colorectal cancer; Guideline adherence; Medical oncologist; Targeted therapy |
| Entry Date(s): | Date Created: 20260606 Date Completed: 20260725 Latest Revision: 20260813 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13401523 |
| DOI: | 10.1007/s10147-026-03069-0 |
| PMID: | 42250141 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1437-7772 |
|---|---|
| DOI: | 10.1007/s10147-026-03069-0 |